X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (452) 452
Publication (57) 57
Magazine Article (8) 8
Conference Proceeding (2) 2
Dissertation (2) 2
Newspaper Article (2) 2
Book Chapter (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (110) 110
hematology (103) 103
male (89) 89
female (83) 83
adult (80) 80
middle aged (79) 79
index medicus (61) 61
medicine, research & experimental (51) 51
aged (45) 45
adolescent (38) 38
oncology (38) 38
diseases of the blood and blood-forming organs (33) 33
aged, 80 and over (25) 25
chronic myeloid leukemia (25) 25
medicine (25) 25
treatment outcome (24) 24
leukemia (22) 22
medicine, general & internal (22) 22
hematopoietic stem cell transplantation (21) 21
prognosis (21) 21
young adult (21) 21
child (20) 20
risk factors (18) 18
brazil (17) 17
hemic and lymphatic diseases (17) 17
prospective studies (17) 17
cancer (16) 16
retrospective studies (16) 16
antineoplastic agents - therapeutic use (15) 15
child, preschool (15) 15
imatinib mesylate (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (15) 15
survival (15) 15
transplantation (15) 15
bone marrow transplantation (14) 14
chemotherapy (14) 14
pyrimidines - therapeutic use (14) 14
time factors (14) 14
chronic myelogenous leukemia (13) 13
mortality (13) 13
original (13) 13
disease-free survival (12) 12
multiple myeloma (12) 12
survival analysis (12) 12
dasatinib (11) 11
disease (11) 11
follow-up (11) 11
genetic aspects (11) 11
pyrimidines - adverse effects (11) 11
therapy (11) 11
tilápia do nilo (11) 11
transplantation, homologous (11) 11
tyrosine kinase inhibitors (11) 11
bone-marrow-transplantation (10) 10
care and treatment (10) 10
imatinib (10) 10
immunology (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - genetics (10) 10
lymphoma (10) 10
lymphomas (10) 10
management (10) 10
original article (10) 10
piperazines - therapeutic use (10) 10
research (10) 10
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - adverse effects (9) 9
cml (9) 9
diagnosis (9) 9
follow-up studies (9) 9
gene frequency (9) 9
health aspects (9) 9
hematology, oncology and palliative medicine (9) 9
hematopoietic stem cell transplantation - adverse effects (9) 9
hematopoietic stem cells (9) 9
infectious diseases (9) 9
protein kinase inhibitors - therapeutic use (9) 9
bone marrow (8) 8
bone marrow transplantation - adverse effects (8) 8
cells (8) 8
genotype (8) 8
graft vs host disease (8) 8
gvhd (8) 8
nilotinib (8) 8
patients (8) 8
piperazines - adverse effects (8) 8
acute disease (7) 7
analysis (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
benzamides (7) 7
citocinas (7) 7
cytokines (7) 7
drug therapy (7) 7
expression (7) 7
fusion proteins, bcr-abl - genetics (7) 7
graft vs host disease - etiology (7) 7
hodgkin's disease (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - pathology (7) 7
oreochromis niloticus (7) 7
protein-tyrosine kinases - antagonists & inhibitors (7) 7
pyrimidines - administration & dosage (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
Leukemia Research, ISSN 0145-2126, 10/2019, Volume 85, pp. S5 - S6
Journal Article
Leukemia Research, ISSN 0145-2126, 10/2019, Volume 85, pp. S5 - S6
Journal Article
Valuation of cottonseed meal in food of Nile tilapia (Oreochromis niloticus   , L.) fingerlings, 12/2003
The experiment was carried out with the objective of evaluating the Nile tilapia fingerlings performance under different levels of cottonseed meal (CM)... 
cotton meal, Nile tilapia, Oreochromis niloticus, performance | desempenho, farelo de algodão, Oreochromis niloticus, tilápia do Nilo
Journal
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 9, pp. 1353 - 1360
Journal Article
Journal Article
Leukemia Research, ISSN 0145-2126, 2014, Volume 38, pp. S20 - S21
Journal Article
Journal Article